Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
28 févr. 2023 02h00 HE
|
Hofseth Biocare ASA
Bomi Framroze Holding AS, a close associate of primary insider and Chief Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27 February 2023 purchased 200,000 shares in HBC at...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
17 févr. 2023 02h00 HE
|
Hofseth Biocare ASA
Christoph Baldegger, primary insider and member of the board of directors in Hofseth BioCare ASA ("HBC") has today purchased 100,000 shares in HBC at an average price of NOK 2.72 per share. As a...
Hofseth Biocare ASA:
15 févr. 2023 12h12 HE
|
Hofseth Biocare ASA
Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 ...
Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
15 févr. 2023 12h12 HE
|
Hofseth Biocare ASA
Hofseth International AS ("HI"), a close associate of Hofseth Biocare ASA's (the "Company") board member Roger Hofseth, has notified the Company that HI has made the following purchases of shares in...
Hofseth Biocare ASA: FOURTH QUARTER 2022 & FULL YEAR FINANCIAL REPORT
10 févr. 2023 02h00 HE
|
Hofseth Biocare ASA
In Q4, the ingredients business continued to show favorable momentum with growth of 87 %, compared to same quarter last year on an underlying basis, generating sales revenues of NOK 34m, compared to...
Hofseth Biocare ASA: MANDATORY NOTIFICATION OF TRADE
30 déc. 2022 04h08 HE
|
Hofseth Biocare ASA
Ødegård Prosjekt AS, a wholly owned company of Jon Olav Ødegård has today, 30 December 2022, bought 70,000 shares at an average price of NOK 2.91 per share. Jon Olav Ødegård is CEO and primary insider...
Hofseth Biocare ASA: THIRD QUARTER 2022 FINANCIAL REPORT
11 nov. 2022 02h00 HE
|
Hofseth Biocare ASA
Highlights in the third quarter - HBC grew revenue by 105 % year-on-year shows strength of our business in uncertain times and during the third quarter, HBC signed contracts with new salmon...
Hofseth Biocare ASA: STANFORD SCHOOL OF MEDICINE SUCCESSFULLY COMPLETES PRE-CLINICAL TRIAL WORK TESTING PROGO® BIOACTIVE PEPTIDES IN EFFECTIVE GUT HEALTH SUPPORT
17 oct. 2022 03h24 HE
|
Hofseth Biocare ASA
The study, published in prestigious peer-reviewed journal Biomolecules by MDPI, was conducted through a collaboration between Hofseth BioCare (HBC) and Stanford University School of Medicine. It aimed...
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
30 août 2022 08h25 HE
|
Hofseth Biocare ASA
The Extraordinary General Meeting in Hofseth BioCare ASA was held at the premises of the Company in Ålesund, Norway today Tuesday 30 August 2022. All matters were approved according to the...
Hofseth Biocare ASA: HBC’S PROGO BIOACTIVE PEPTIDES NOW IS A “NEW DIETARY INGREDIENT” (NDI) FOR THE US FDA
29 août 2022 02h44 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights...